Precigen (NASDAQ:PGEN) CFO Harry Jr. Thomasian Sells 28,571 Shares

Precigen, Inc. (NASDAQ:PGEN) CFO Harry Jr. Thomasian sold 28,571 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $5.78, for a total value of $165,140.38. Following the transaction, the chief financial officer directly owned 525,964 shares in the company, valued at $3,040,071.92. The trade was a 5.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harry Jr. Thomasian also recently made the following trade(s):

• On Wednesday, July 1st, Harry Jr. Thomasian sold 171,429 shares of Precigen stock. The shares were sold at an average price of $5.53, for a total transaction of $948,002.37.
• On Thursday, May 28th, Harry Jr. Thomasian sold 41,884 shares of Precigen stock. The shares were sold at an average price of $4.36, for a total transaction of $182,614.24.

Precigen Stock Down 7.9%

Shares of PGEN traded down $0.45 during trading hours on Wednesday, hitting $5.25. The company had a trading volume of 7,446,304 shares, compared to its average volume of 4,558,847. The company has a market capitalization of $1.87 billion, a PE ratio of -4.45 and a beta of 1.06. The company has a current ratio of 4.82, a quick ratio of 4.12 and a debt-to-equity ratio of 4.62. The company’s fifty day moving average price is $4.40 and its two-hundred day moving average price is $4.21. Precigen, Inc. has a one year low of $1.45 and a one year high of $6.04.

Precigen (NASDAQ:PGEN) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. The business had revenue of $23.25 million during the quarter, compared to analyst estimates of $20.81 million. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. As a group, equities analysts forecast that Precigen, Inc. will post -0.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Precigen

A number of institutional investors and hedge funds have recently made changes to their positions in PGEN. Boxer Capital Management LLC acquired a new position in Precigen during the 3rd quarter worth about $2,796,000. Occam Crest Management LP increased its position in shares of Precigen by 29.6% in the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock valued at $14,637,000 after purchasing an additional 799,339 shares during the last quarter. Investment Insight Wealth Management LLC acquired a new stake in Precigen in the fourth quarter valued at $443,000. UBS Group AG lifted its stake in Precigen by 41.4% during the fourth quarter. UBS Group AG now owns 891,428 shares of the biotechnology company’s stock worth $3,726,000 after purchasing an additional 260,824 shares during the last quarter. Finally, Impala Asset Management LLC purchased a new stake in shares of Precigen during the 4th quarter worth approximately $690,000. 33.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on PGEN. Wall Street Zen downgraded shares of Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. HC Wainwright raised their price objective on shares of Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Citigroup restated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research report on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $12.50.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.